The HEOR Advantage: Building Payer-Ready GVDs
In the biotech space, innovation alone isn’t enough — success hinges on proving both clinical and economic value. This blog explores why Health Economics and Outcomes Research (HEOR) should be a strategic pillar, not a back-office function, and how companies can embed it across the drug development lifecycle to accelerate market access and adoption.
In the biotech space, innovation alone isn’t enough success hinges on proving both clinical and economic value. This blog explores why Health Economics and Outcomes Research (HEOR) should be a strategic pillar, not a back-office function, and how companies can embed it across the drug development lifecycle to accelerate market access and adoption through modern Pharma digital transformation and evidence-driven strategies.
Know More About The HEOR Advantage: Building Payer-Ready GVDs : https://www.agilisium.com/blog....s/the-heor-advantage
